Acute alcoholic hepatitis

Journal of Clinical Gastroenterology

Volumn 40, Issue 9, 2006, Pages 833-841

  Ceccanti, Mauro ^a   Attili, Adolfo ^a   Balducci, Giuseppe ^b   Attilia, Fabio ^a   Giacomelli, Stefano ^a   Rotondo, Claudia ^a   Sasso, Guido Francesco ^a   Xirouchakis, Elias ^c   Attilia, Maria Luisa ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c 1st IKA Hospital   (Greece)

Author keywords

Alcohol liver disease; Alcoholic hepatitis; Alcoholism

Indexed keywords

ALPHA TOCOPHEROL; BENZODIAZEPINE; COLCHICINE DERIVATIVE; CORTICOSTEROID; ENDOTOXIN; ETANERCEPT; GLUCOCORTICOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; LIVER PROTEIN; PENICILLAMINE; PENTOXIFYLLINE; PREDNISOLONE; PREDNISONE; PROPYLTHIOURACIL; STEROID; THIOL DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1;

ALCOHOL ABSTINENCE; ALCOHOL ABUSE; ALCOHOL LIVER DISEASE; ALCOHOL METABOLISM; FIBROBLAST; GASTROINTESTINAL HEMORRHAGE; HEPATORENAL SYNDROME; HUMAN; IMMUNE RESPONSE; INFECTION; LIVER DISEASE; LIVER GRAFT; LUNG ASPERGILLOSIS; MORTALITY; OXIDATION REDUCTION STATE; PATHOLOGY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PSYCHOLOGIC ASSESSMENT; REVIEW; SURVIVAL RATE; TUBERCULOSIS;

ACUTE DISEASE; ANIMALS; ETHANOL; HEPATITIS, ALCOHOLIC; HEPATOCYTES; HEPATORENAL SYNDROME; HUMANS; LIPOPOLYSACCHARIDES; LIVER TRANSPLANTATION; PROGNOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33749407401     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000225570.04773.5d     Document Type: Review

References (98)

1. Maddrey WC. Alcoholic hepatitis: pathogenesis and approaches to treatment. Scand J Gastroenterol. 1990;25 (suppl):118-130.
2. Diagnostic and Statistical Manual of Mental Disorders. DSM-IV-TR, Am Psychiatric Assoc. 2000:235-247.
3. Mailliard ME, Sorrel MF. Alcoholic liver disease. In: Kasper DL, Braunwald E, Fauci AS, et al. eds. Harrison's Principles of Internal Medicine. New York: McGraw Hill; 2001:1885-1858.
4. Maher JJ. Alcoholic liver disease. In: Feldman M, Sleisenger MH, Scharschmidt BF, et al. eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Philadelphia: WB Saunders Co; 1998:1199-2010.
5. Saito H, Ishii H. Recent understanding of immunological aspects in alcoholic hepatitis. Hepatol Res. 2004;30:193-198.
6. Niemela O, Juvonen T, Parkkila S. Immunohistochemical demonstration of acetaldehyde-modified epitopes in human liver after alcohol consumption. J Clin Invest. 1991;87:1367-1374.
7. Clot P, Parola M, Bellomo G, et al. Plasma membrane hydroxyethyl radical adducts cause antibody-dependent cytotoxicity in rat hepatocytes exposed to alcohol. Gastroenterol. 1997;113:265.
8. Loguercio C, Federico A. Oxidative stress in viral and alcoholic hepatitis. Free Radic Biol Med. 2003;34:1-10.
9. Chedid A, Mendenhall CL, Gartside P, et al. Prognostic factors in alcoholic liver disease. VA Cooperative Study Group. Am J Gastroenterol. 1991;86:210-216.
10. Purohit V, Russo D. Cellular and molecular mechanisms of alcoholic hepatitis: introduction and summary of the symposium. Alcohol. 2002;27:3-6.
11. Rapporto EURISPES, 2003.
12. Bui Han SH. Alcoholic hepatitis. Curr Treat Options Gastroenterol. 2001;4:511-516.
13. Fujimoto M, Uemura M, Kojima H, et al. Prognostic factors in severe alcoholic liver injury. Nara Liver Study Group. Alcohol Clin Exp Res. 1999;23(suppl 4):33S-38S.
14. Morgan MY. The prognosis and outcome of alcoholic liver disease. Alcohol Alcohol Suppl. 1994;2:335-343.
15. O'Keefee C, McCormick PA. Severe acute alcoholic hepatitis: an audit of medical treatment. Ir Med J. 2002;95:108-109, 111.
16. Maher JJ. Treatment of alcoholic hepatitis. Gastroenterol Hepatol. 2002;17:48-55.
17. Huang YS, Chan CY, Wu JC, et al. Serum levels of interleukin-8 in alcoholic liver disease: relationship with disease stage, biochemical parameters and survival. J Hepatol. 1996;24:377-384.
18. Wallgren H. Absorption, diffusion, distribution and elimination of ethanol: effect on biological membranes. In: International Encyclopedia of Pharmacology and Therapeutics. Vol. 1. Oxford: Pergamon; 1970:161-188.
19. Lieber CS. Ethanol metabolism, cirrhosis and alcoholism. Clin Chim Acta. 1997;257:59-84.
20. Lieber CS. Biochemical and molecular basis of alcohol-induced injury to liver and other tissues. NEJM. 1988;319:1639-1650.
21. Lautenburg BH, Davies S, Mitchell JR. Ethanol suppresses hepatic glutathione synthesis in rats in vivo. J Pharm Exp Ther. 1984;230:7-11.
22. Niemela O, Klajner F, Orrego H, et al. Antibodies against qacetaldheide-modified protein hepitopes in human alcoholics. Hepatology. 1987;7:210-214.
23. Sato S, Nouchi T, Worner TM, et al. liver fibrosis in alcoholics: detection of Fab radioimmunassay of serum procollagen III peptides. JAMA. 1986;256:1471-1473.
24. Lieber CS. Cytochrome P-4502E1: its physiological and pathological role. Physiol Rev. 1997;77:517-544.
25. Williams AJK, Barry Re. Free radical generation by neutrophils: a potential mechanism of cellular injury in acute alcoholic hepatitis. Gut. 1987;28:1157-1161.
26. Fukui H, Brauner B, Bode JC et al. Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: reevaluation with an improved chromogenic assay. J Hepatol. 1991;12:162-169.
27. Adachi Y, Bradford BU, Gao W et al. Inactivation of Kupffer cells prevents early alcohol-induced liver injury. Hepatology. 1994;20:453-460.
28. McClain CJ, Cohen DA. Increased tumor necrosis factor production by monocytes in alcoholic hepatitis. Hepatology. 1989;9:349-351.
29. Muto Y, Nouri-Aria KT, Meager A, et al. Enhanced tumor necrosis factor and interleukin-1 in fulminant hepatic failure. Lancet. 1988;2:72-74.
30. Li L, Coursat S, Hu J, et al. Characterization of IRAK in normal and endotoxin tolerant cells. J Biol Chem. 2000;275:2410-2414.
31. Wheeler Mz. Endotoxin and Kupffer cell activation in alcoholic liver disease. Alcohol Research & Health (Bethesda). 2003;27:300-306.
32. Mathurin P, Deng QG, Keshavarzian A, et al. Exacerbation of alcoholic liver injury by enteral endotoxin in rats. Hepatology. 2000;32:1008-1017.
33. Fernandez-Checa JC, Kaplowitz N, Colell A, et al. Oxidative stress and alcoholic liver disease. Alcohol Health Res World. 1997;21:321-324.
34. Ding WX, Yin XM. Dissection of the multiple mechanisms of TNF-α-induced apoptosis in liver injury. J Cell Mol Med. 2004;8:445-454.
35. Bailey SM, Cunninghan CC. Contribution of mitochondria to oxidative stress associated with alcoholic liver disease. Free Radical Biol Med. 2002;32:11-16.
36. Hoek JB, Pastorino JG. Ethanol, oxidative stress, and cytokine-induced liver cell injury. Alcohol. 2002;27:63-68.
37. Yin XM, Ding WM. Death receptor activation-induced hepatocyte apoptosis and liver injury. Curr Mol Med. 2003;3:491-508.
38. Hoek JB, Cahill A, Pastorino JG. Alcohol and mitochondria: a dysfunctional relationship. Gastroenterol. 2002;122:2049-2063.
39. Fujimoto M, Uemura M, Nakatani Y, et al. Plasma endotoxin and serum cytokine levels in patients with alcoholic hepatitis: relation to severity of liver disturbance. Alcohol Clin Exp Res. 2000;24(suppl 4):48S-54S.
40. Naveau S, Balian A, Capron F, et al. Balance between pro and anti-inflammatory cytokines in patients with acute alcoholic hepatitis. Gastroenterol Clin Biol. 2005;29:269-274.
41. Takahashi T, So-Wan T, Kamimura T, et al. Infiltrating polymorphonuclear leukocytes and apoptotic bodies derived from hepatocytes but not from ballooning hepatocytes containing Mallory bodies show nuclear DNA fragmentation in alcoholic hepatitis. Alcohol Clin Exp Res. 2000;24(suppl 4):68S-73S.
42. Jaeschke H. Neutrophil-mediated tissue injury in alcoholic hepatitis. Alcohol. 2002;27:23-27.
43. Parlesak A, Schafer C, Bode C. IgA against gut-derived endotoxins: does it contribute to suppression of hepatic inflammation in alcohol-induced liver disease? Dig Dis Sci. 2002;47:760-766.
44. Spahr L, Rubbia-Brandt L, Pugin J, et al. Rapid changes in alcoholic hepatitis histology under steroids: correlation with soluble intercellular adhesion molecule-1 in hepatic venous blood. J Hepatol. 2001;35:582-589.
45. Bird GL, Sheron N, Goka AK, et al. Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann Intern Med. 1990;112:917-920.
46. Naveau S, Emilie D, Balian A, et al. Plasma levels of soluble tumor necrosis factor receptors p55 and p75 in patients with alcoholic liver disease of increasing severity. J Hepatol. 1998;28:778-784.
47. Natori S, Rust C, Stadheim LM, et al. Hepatocyte apoptosis is a pathologic feature of human alcoholic hepatitis. J. Hepatol. 2001;34:248-253.
48. Tagami A, Ohnishi H, Moriwaki H, et al. Fas-mediated apoptosis in acute alcoholic hepatitis. Hepatogastroenterology. 2003;50:443-448.
49. Yin M, Wheeler M, Kono H, et al. Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology. 1999;117:942-952.
50. Mookerjee RP, Sen S, Davies NA, et al. Tumour necrosis factor alpha is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis. Gut. 2003;52:1182-1187.
51. Iimuro Y, Gallucci R, Luster M, et al. Antibodies to tumor necrosis factor alpha attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. Hepatology. 1997;26:1530-1537.
52. Friedman SL. Molecular mechanisms of hepatic fibrosis and principles of therapy. J Gastroenterol. 1997;32:424-430.
53. Sasso GF, Attilia ML, Attilia F, et al. Marker Biologici Dell'abuso Alcolico. Roma: SITAC; 2004.
54. Stibler H, Borg S, Joustra N. A modified method for the assay of carbohydrate-deficient transferrin (CDT) in serum. Alcohol Alcoholism. 1991;1:451-454.
55. Kumashiro R, Sata M, Ishii K, et al. Prognostic factors for short-term survival in alcoholic hepatitis in Japan: analysis by logistic regression. Alcohol Clin Exp Res. 1996;20(suppl 9):383A-386A.
56. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464-470.
57. Cardenas A. Hepatorenal syndrome: a dreaded complication of end-stage liver disease. Am J Gastroenterol. 2005;100:460-467.
58. Han SH, Rice S, Cohen SM, et al. Duplex Doppler ultrasound of the hepatic artery in patients with acute alcoholic hepatitis. J Clin Gastroenterol. 2002;34:573-577.
59. Wanless IR, Lenz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology. 1990;12:1006-1013.
60. Kulkarni K, Tran T, Medrano M, et al. The role of the discriminant factor in the assessment and treatment of alcoholic hepatitis. J Clin Gastroenterol. 2004;38:453-459.
61. Carithers JRL, Herlong HF, Diehl AM, et al. Metilprednisolone therapy in patients with severe alcoholic hepatitis. Ann Intern Med. 1989;110:585-590.
62. Mathurin P, Mendenhall CL, Carithers RL Jr, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol. 2002;36:480-487.
63. Sheth M, Riggs M, Patel T. Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol. 2002;2:2.
64. Tilgh H, Kaser A. Predicting mortality by the Glasgow alcoholic hepatitis score: the long awaited progress? Gut. 2005;54:1057-1059.
65. Forrest EH, Evans CDJ, Stewart S, et al. Analysis of factor predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut. 2005;54:1174-1179.
66. Pares A, Cabelleira J, Bruguera M, et al. Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage. J Hepatol. 1986;2:33-42.
67. Rambaldi A, Gluud C. Meta-analysis of propylthiouracil for alcoholic liver disease - a Cochrane Hepato-Biliary Group review. Liver. 2001;21:398-404.
68. Mezey E, Potter JJ, Rennie-Tankersley L, et al. A randomized placebo controlled trial of vitamin E for alcoholic hepatitis. J Hepatol. 2004;40:40-46.
69. Akriviadis EA, Steindel H, Pinto PC. Failure of colchicine to improve short-term survival in patients with alcoholic hepatitis. Gastroenterology. 1990;99:811-818.
70. Bird GL, Prach AT, McMahon AD. Randomised controlled double-blind trial of the calcium channel antagonist amlodipine in the treatment of acute alcoholic hepatitis. J Hepatol. 1998;28:194.
71. Lieber CS, Casini A, De Carli LM. S-adenosyl-L-methionine attenuates alcohol-induced liver injury in the baboon. Hepatology. 1990;11:165-172.
72. Mato JM, Camara J, Fernandez de Paz J, et al. S-adenosylmethionine in alcoholic cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol. 1999;30:1081-1089.
73. Lieber CS. S-Adenosyl-L-methionine and alcoholic liver disease in animal models: implications for early intervention in human beings. Alcohol. 2002;27:173-177.
74. Nordmann R, Ribiere C, Rouach H. Implication of free radical mechanisms in ethanol-induced cellular injury. Free Radic Biol Med. 1992;12:219-240.
75. Lee TD, Sadda MR, Mendler MH, et al. Abnormal hepatic methionine and glutathione metabolism in patients with alcoholic hepatitis. Alcohol Clin Exp Res. 2004;28:173-181.
76. Carithers RL Jr, Herlong HF, Diehl AM. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med. 1989;110:685-690.
77. Imperiale TF, McCullough AJ. Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. Ann Intern Med. 1990;113:299-307.
78. Maher JJ. Treatment of alcoholic hepatitis. J Gastroenterol Hepatol. 2002;17:448-455.
79. Kulkarni K, Tran T, Medrano M, et al. The role of the discriminant factor in the assessment and treatment of alcoholic hepatitis. J Clin Gastroenterol. 2004;38:453-459.
80. Mathurin P, Abdelnour M, Ramond MJ, et al. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology. 2003;38:1363-1369.
81. Duvoux C, Radier C, Roudot-Thoraval F, et al. Low-grade steatosis and major changes in portal flow as new prognostic factors in steroid-treated alcoholic hepatitis. Hepatology. 2004;40:1370-1378.
82. Alvarez MA, Cabre E, Lorenzo-Zuniga V, et al. Combining steroids with enteral nutrition: a better therapeutic strategy for severe alcoholic hepatitis? Results of a pilot study. Eur J Gastroenterol Hepatol. 2004;16:1375-1380.
83. Strieter R, Remick D, Ward P, et al. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun. 1988;155:1230-1236.
84. Haber PS, Warner R, Seth D, et al. Pathogenesis and management of alcoholic hepatitis. J Gastroenterol Hepatol. 2003;18:1332-1344.
85. Akriviadis E, Botla R, Briggs W. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119:1637-1648.
86. Sen S, Mookerjee RP, Cheshire LM, et al. Albumin dialysis reduces portal pressure acutely in patients with severe alcoholic hepatitis. J Hepatol. 2005;43:142-148.
87. Jalan R, Sen S, Steiner C, et al. Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis. J Hepatol 2003;38:24-31.
88. Tsuji Y, Kumashiro R, Ishii K, et al. Severe alcoholic hepatitis successfully treated by leukocytapheresis: a case report. Alcohol Clin Exp Res. 2003;27(suppl 8):26S-31S.
89. Tilg H, Jalan R, Kaser A, et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol. 2003;38:419-425.
90. De Rosa FG, Shaz D, Campagna AC, et al. Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis-factor-alpha-neutralizing antibody: a possible healthcare-associated case? Infect Control Hosp Epidemiol. 2003;2:477-482.
91. Arend SM, Breedveld FC, van Dissel JT. TNF-alpha blockade and tuberculosis: better look before you leap. Neth J Med. 2003;61:111-119.
92. Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology (Oxford). 2005; [Epub ahead of print].
93. Spahr L, Rubbia-Brandt L, Frossard JL, et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol. 2002;37:448-455.
94. Naveau S, Chollet-Martin S, Dharancy S, et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology. 2004;39:1390-1397.
95. Menon KV, Stadheim L, Kamath PS, et al. A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol. 2004;99:255-260.
96. Wheeler MD, Kono H, Yin M, et al. Delivery of the Cu/Zn-superoxide dismutase gene with adenovirus reduces early alcohol-induced liver injury in rats. Gastroenterology. 2001;120:1241-1250.
97. Uesugi T, Froh M, Arteel GE, et al. Delivery of IkappaB superrepressor gene with adenovirus reduces early alcohol-induced liver injury in rats. Hepatology. 2001;34:1149-1157.
98. Dagher L, Patch D, Marley R, et al. Review article: pharmacological treatment of the hepatorenal syndrome in cirrhotic patients. Aliment Pharmacol Ther. 2000;14:515-521.